Rheumatology
Conference Coverage
Refining SLE cardiovascular risk estimation
WASHINGTON – RBC distribution width predicts major adverse cardiovascular events.
News from the FDA/CDC
Just the FRAX: National fracture risks estimated
A risk-estimating algorithm puts 10-year probability of major osteoporotic fracture at 5.3% in adults aged 40 years and over.
From the Journals
RA treatment delays raise risk of long-term disability
Early initiation of treatment for rheumatoid arthritis is associated with reduced disability scores as much as 2 decades later.
From the Journals
Short course of prednisolone may help distinguish between RA and hand OA
A 3-day course of prednisolone may help clinicians to decide if patients have RA, but the test should not be used in isolation of other surrogate...
From the Journals
Triple therapy found as ‘durable’ as biologic after methotrexate failure
RA patients stay on triple therapy at least as often and with the same results as do those who take a methotrexate-etanercept combination over the...
Conference Coverage
Lupus low disease activity definition gains momentum
MELBOURNE – Evidence for the validity of using Lupus Low Disease Activity State (LLDAS) as a measurement tool both in clinical trials and clinical...
From the Journals
Study shows no adverse events with long-term denosumab in postmenopausal women
Denosumab, taken long term, is not linked with any adverse events, an analysis of the participants in the FREEDOM trial showed.
From the Journals
CCP status doesn’t influence tocilizumab’s effectiveness in RA
Cyclic citrullinated peptide seronegativity did not improve tocilizumab response in real-world patients.
Conference Coverage
MicroRNAs linked to treatment response in lupus nephritis
MELBOURNE – Expression of six microRNAs in kidney biopsy samples helped to predict response to cyclophosphamide.
From the Journals
Obesity in women with RA greatly influences CRP levels
A study’s findings suggest interpreting C-reactive protein levels cautiously in obese women with rheumatoid arthritis.
From the Journals
Secukinumab beat etanercept in 52-week psoriasis quality of life analysis
Secukinumab was associated with faster and greater improvements in self-reported quality of life in psoriasis patients, compared with etanercept...